Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

被引：0
|
作者：
Y. F. Yu
Y. Wang
T. P. Fu
K. Chen
J. Q. Liu
H. R. Yao
机构：
[1] Sun Yat-sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center
[2] Sun Yat-sen University,Department of Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] Sun Yat-sen University Cancer Center,Department of Oncology
[4] Sun Yat-sen Memorial Hospital,undefined
[5] Sun Yat-sen University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 168卷
关键词：
Metastatic breast cancer; HER2-positive; Trastuzumab; Single-agent chemotherapy; Doublet-agent chemotherapy; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 348
页数：11
相关论文
共 50 条
  • [41] Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer
    A. H. Kamal
    F. Camacho
    R. Anderson
    W. Wei
    R. Balkrishnan
    G. Kimmick
    Breast Cancer Research and Treatment, 2012, 134 : 371 - 378
  • [42] Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
    Moriwaki, Kensuke
    Uechi, Saki
    Fujiwara, Takaaki
    Hagino, Yu
    Shimozuma, Kojiro
    PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 437 - 447
  • [43] Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
    Kensuke Moriwaki
    Saki Uechi
    Takaaki Fujiwara
    Yu Hagino
    Kojiro Shimozuma
    PharmacoEconomics - Open, 2021, 5 : 437 - 447
  • [44] PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer
    Vorkas, P. A.
    Agelaki, S.
    Poumpouridou, N.
    Kroupis, C.
    Mavroudis, D.
    Stathopoulos, E.
    Georgoulias, V
    Liandou, E. S.
    CANCER RESEARCH, 2009, 69 (24) : 599S - 599S
  • [45] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Pier Paolo M. Berton Giachetti
    Giuseppe Curigliano
    Nature Reviews Clinical Oncology, 2024, 21 : 171 - 172
  • [46] Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Vogel, CL
    Cobleigh, MA
    Tripathy, D
    Gutheil, JC
    Harris, LN
    Fehrenbacher, L
    Slamon, DJ
    Murphy, M
    Novotny, WF
    Burchmore, M
    Shak, S
    Stewart, SJ
    Press, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) : 719 - 726
  • [47] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Giachetti, Pier Paolo M. Berton
    Curigliano, Giuseppe
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172
  • [48] First-line therapy of advanced HER2-positive breast carcinoma
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 14 - 14
  • [49] Trastuzumab as first-line therapy for metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 776 - 776
  • [50] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
12345